BPA for pluvicto and lutathera injection
Active Awarded
- Contract number
- HT941026FE120
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $205,766
Award facts
- Contract value 100% obligated
- $205,765.56 Current and potential, with all options
- Completion date 34% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency issued a BPA call to Novartis Pharmaceuticals Corporation on August 7, 2026, for PLUVICTO and LUTATHERA injection, with a ceiling value of $205,765.56. The call is priced firm fixed price and was issued without a set-aside. Place of performance is East Hanover, New Jersey 07936, and the period of performance runs through April 30, 2027.
Quick answers
Who was awarded contract HT941026FE120?
HT941026FE120 was awarded to Novartis Pharmaceuticals Corporation by Defense Health Agency (Department of Defense) on August 7, 2026.
How much is contract HT941026FE120 worth?
The government has obligated $205,766 on HT941026FE120.
Is contract HT941026FE120 an order under another contract?
Yes. HT941026FE120 is a BPA call under HT941026AE002, a blanket purchase agreement.
Was contract HT941026FE120 competed?
The extent of competition for HT941026FE120 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award